Thera-SAbDab

ISATUXIMAB

>   Structural Summary
TherapeuticIsatuximab
TargetCD38
Heavy ChainQVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSS
Light ChainDIVMTQSHLSMSTSLGDPVSITCKASQDVSTVVAWYQQKPGQSPRRLIYSASYRYIGVPDRFTGSGAGTDFTFTISSVQAEDLAVYYCQQHYSPPYTFGGGTKLEIK
100% seqID Fv Structure4cmh [Fvs: BC]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Preregistration
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2014
INN Year Recommended2015
Companies InvolvedImmunoGen, Huntsman Cancer Institute, Roche, Sanofi
Conditions Approvedna
Conditions ActiveMultiple myeloma, Acute myeloid leukaemia, Precursor cell lymphoblastic leukaemia-lymphoma, T-cell lymphoma, Colorectal cancer, Diffuse large B cell lymphoma, Hodgkin's disease, Non-small cell lung cancer, Peripheral T-cell lymphoma, Prostate cancer, Solid tumours, Urogenital cancer
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]